Evelo Biosciences, Inc. (Nasdaq:EVLO), Rutgers University, and Robert Wood Johnson University Hospital today announced the submission of an Investigational New Drug (IND) application for an Evelo-sponsored Phase 2 clinical study evaluating the safety and efficacy of EDP1815 for the treatment of hospitalized patients with newly diagnosed COVID-19. The study will be led by Reynold A. Panettieri, Jr., M.D., Vice Chancellor for Translational Medicine and Science at Rutgers Biomedical and Health Sciences and Professor of Medicine at Rutgers Robert Wood Johnson Medical School. To read the full story.
Home / News / Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients
Recent Posts
- Grant Writing Mini Course – Registration Deadline Today!
- New Jersey coasts, lined with toxic facilities, don’t fare well in two new studies.
- Translational Science Competency-Based Assessment Pilot Test Sign Up
- As few as 2 cigarettes per day linked to 50% increased risk of heart disease: Study
- What You Need to Know About ‘Ozempic Face,’ According to Doctors.
Categories
- Community (2,404)
- Covid (993)
- CTO Events (6)
- News (3,046)
- Pilots (21)